Genoskin, a biotechnology company using live ex vivo human skin to test therapeutic and non-therapeutic products, has launched Mantis, a new spatial biology imaging platform dedicated to skin immunology. This new offer was developed by Genoskin’s recently appointed CSO Dr. Nicolas Gaudenzio and his team at Inserm.
What is Mantis?
Mantis is a spatial biology solution designed to analyse human skin and is backed by multiple validated ex vivo human skin platforms. It provides researchers with 3D multiplexed imaging of human skin tissue and enables an unbiased complete immune profiling of skin tissue within its spatial context.
As the tissue’s spatial architecture may affect disease pathology and treatment response, Mantis is positioned to resolve and evaluate the immunomodulatory effects of molecules on skin; upon injection, topical application or systemic administration.
The technology
Mantis incorporates technology licensed from Inserm – the French National Institute of Health and Medical Research. These technologies position Genoskin as a key partner for biopharmaceutical companies, enabling new drug development processes with time and cost savings.
Official comments
Pascal Descargues, CEO of Genoskin, said: “We are thrilled to launch the new Mantis platform that will allow clients in the pharmaceutical industry to study the effects of drugs, including vaccines, on the cutaneous immune system. Mantis relies on the extensive work done by Dr. Gaudenzio and his team to develop this powerful, transversal tool. Joining forces with the Infinity Lab at Inserm to build the MANTIS platform and signing this strategic license agreement has been an amazing journey. We also plan to pursue new co-developments with academic labs. Following the launch of our ISR platform this year, the first ex vivo human skin platform to study injection site reactions, we are continuing our strategic shift and fulfilling Genoskin’s mission of transforming the way drugs are developed today, using human skin as a reliable tool to generate relevant human data.”
Image credit: Genoskin
